Loading...
XKRX
326030
Market cap7.12bUSD
Dec 05, Last price  
134,000.00KRW
1D
-1.69%
1Q
22.71%
IPO
-18.79%
Name

SK Biopharmaceuticals Co Ltd

Chart & Performance

D1W1MN
XKRX:326030 chart
P/E
43.59
P/S
19.16
EPS
3,074.04
Div Yield, %
—
Shrs. gr., 5y
31.95%
Rev. gr., 5y
34.62%
Revenues
547.60b
+54.30%
37,631,486,14051,798,062,83060,454,791,13072,440,821,40071,416,701,94089,927,545,43085,316,069,9501,098,738,190123,852,416,02025,999,026,720418,644,529,120246,179,120,020354,891,555,520547,596,283,000
Net income
240.74b
P
-19,465,137,000-30,330,598,000-41,001,914,000-37,048,875,000-28,061,186,000-30,360,843,000-97,649,060,000-138,096,479,000-71,519,466,820-247,413,613,86064,845,640,000-139,430,877,680-32,882,849,240240,738,038,000
CFO
94.90b
P
-16,962,588,800-24,065,043,200-39,064,435,900-40,336,395,590-28,716,692,010-48,941,251,590-98,342,730,340-141,281,399,300-81,334,671,550-210,726,008,610-92,871,732,620-159,920,061,630-94,201,249,07094,899,993,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.
URL
https://www.skbp.com/
IPO date
Jul 02, 2020
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT